stockrowGuardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
Follow GH
Alert me
Guardant Health, Inc. (GH) EPS (diluted)
Guardant Health, Inc.'s EPS (diluted) for fiscal 2025 was −$3.32, compared with −$3.56 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$3.68. Over the past ten years it has ranged from −$6.61 (fiscal 2017) to −$0.84 (fiscal 2019); the current reading is higher than 70% of that period. EPS (diluted) has risen for 3 consecutive fiscal years. Guardant Health, Inc. ranks 42nd of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.32 | — |
| FY2024 | −$3.56 | — |
| FY2023 | −$4.28 | — |
| FY2022 | −$6.41 | — |
| FY2021 | −$4.00 | — |
| FY2020 | −$2.60 | — |
| FY2019 | −$0.84 | — |
| FY2018 | −$2.80 | — |
| FY2017 | −$6.61 | — |
| FY2016 | −$3.53 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.93 | — |
| Jun 2026 | −$0.90 | — |
| Mar 2026 | −$0.85 | — |
| Dec 2025 | −$1.00 | — |
| 32 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $44.43 |
| MEDP Medpace Holdings, Inc. compare | $18.04 |
| LH Labcorp Holdings Inc. compare | $12.19 |
| DGX Quest Diagnostics Incorporated compare | $10.04 |
| ILMN Illumina, Inc. compare | $5.81 |
| ICLR ICON PLC compare | $5.81 |
| RVTY Revvity Inc. compare | $2.26 |
| CRL Charles River Laboratories International, Inc. compare | $0.93 |
| GH Guardant Health, Inc. | −$3.68 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on GH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement